News | Ventricular Assist Devices (VAD) | June 11, 2015

ECRI Institute Review Supports Impella RP Device

Overview of published articles indicates significant improvement in hemodynamics with high short- and long-term survival rates

ECRI Institute, review, Impella RP, Abiomed

June 11, 2015 - ECRI Institute recently reviewed published data on Abiomed's Impella RP (Right Percutaneous) transcatheter ventricular assist device (VAD). The institute said the device provides immediate significant improvements in hemodynamics with considerable short-term and long-term survival rates.

The Impella RP is a catheter-based intracardiac microaxial blood pump to support short-term pulmonary circulation in pediatric or adult patients. It is intended to provide percutaneous circulatory support to restore normal right heart hemodynamics, reduce right ventricular work, and enable the right heart to potentially recover or sustain the patient until the next therapy.

ECRI searched PubMed, EMBASE and selected Web-based resources for relevant documents published between Jan. 1, 2010, and April 30, 2015. The healthcare technology research firm identified two small nonrandomized comparison studies and three small cohort studies (two of which were retrospective) reporting on 138 patients.

Review of the abstracts of published articles suggests that Impella RP provides immediate significant improvements in hemodynamics with short-term (30 days) and long-term (1 year) survival rates of approximately 70 and 50 percent, respectively. Study populations were small and consisted of mostly male adults with acute right heart failure. Only one study reported on adverse events.

ECRI was unable to determine whether Impella RP works better than similar right ventricular assist devices (e.g., Excor Pediatric VAD, Percutaneous ventricular assist device [PVAD]/implantable ventricular assist device [IVAD] or CentriMag right ventricular assist device [RVAD]) because no studies were available that compare the devices.

The ECRI Institute is an independent nonprofit organization that conducts research into the most effective approaches for improving patient care.  

For more information: www.ecri.org


Related Content

News | Heart Failure

Aug. 14, 2025 — Analytics For Life, in collaboration with its U.S. commercial partner CorVista Health, announced they ...

Home August 15, 2025
Home
News | Heart Failure

Aug. 6, 2025 — Ventric Health, a medtech company enabling early detection of heart failure (HF) in a primary care ...

Home August 06, 2025
Home
News | Heart Failure

July 14, 2025 — Bayer has announced that the U.S. Food and Drug Administration (FDA) approved KERENDIA (finerenone) to ...

Home July 14, 2025
Home
News | Heart Failure

June 23, 2025 — iRhythm Technologies, Inc. announced the results from two large-scale real-world studies presented at ...

Home June 25, 2025
Home
News | Heart Failure

June 3, 2025 — Bayer announced it will present multiple new analyses of the Kerendia (finerenone) clinical trial program ...

Home June 04, 2025
Home
News | Heart Failure

March 25, 2025 — Bayer plans to present data from 13 new analyses from across the KERENDIA (finerenone) comprehensive ...

Home March 25, 2025
Home
News | Heart Failure

March 17, 2025 — Bayer recently announced that the U.S. Food and Drug Administration (FDA) accepted its supplemental new ...

Home March 21, 2025
Home
News | Heart Failure

Jan. 7, 2025 — FIRE1 recently announced it has received Breakthrough Device Designation from the U.S. Food and Drug ...

Home January 07, 2025
Home
News | Heart Failure

Heart failure is a rapidly growing public health issue that can be difficult to manage on a global scale. But there are ...

Home October 02, 2024
Home
News | Heart Failure

Sept. 30, 2024 — Cytokinetics, Inc. recently announced that additional analyses synthesizing data from SEQUOIA-HCM ...

Home October 02, 2024
Home
Subscribe Now